Standard BioTools Inc.

Symbol: LAB

NASDAQ

2.41

USD

Market price today

  • -2.5738

    P/E Ratio

  • -0.0737

    PEG Ratio

  • 923.15M

    MRK Cap

  • 0.00%

    DIV Yield

Standard BioTools Inc. (LAB) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.47%

Operating Profit Margin

-0.66%

Net Profit Margin

-0.70%

Return on Assets

-0.23%

Return on Equity

1.67%

Return on Capital Employed

-0.33%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO:Dr. Michael Egholm Ph.D.
Full-time employees:534
City:South San Francisco
Address:2 Tower Place
IPO:2011-02-10
CIK:0001162194

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.472% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.659%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.702%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.231% return, is a testament to Standard BioTools Inc.'s adeptness in optimizing resource deployment. Standard BioTools Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.668%. Furthermore, the proficiency of Standard BioTools Inc. in capital utilization is underscored by a remarkable -0.328% return on capital employed.

Stock Prices

Standard BioTools Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.61, while its low point bottomed out at $2.44. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Standard BioTools Inc.'s stock market.

Liquidity Ratios

Analyzing LAB liquidity ratios reveals its financial health of the firm. The current ratio of 144.72% gauges short-term asset coverage for liabilities. The quick ratio (123.08%) assesses immediate liquidity, while the cash ratio (47.29%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio144.72%
Quick Ratio123.08%
Cash Ratio47.29%

Profitability Ratios

LAB profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -69.78% underscores its earnings before tax deductions. The effective tax rate stands at -0.61%, revealing its tax efficiency. The net income per EBT, 100.61%, and the EBT per EBIT, 105.82%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -65.94%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-69.78%
Effective Tax Rate-0.61%
Net Income per EBT100.61%
EBT per EBIT105.82%
EBIT per Revenue-65.94%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.45, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding123
Days of Inventory Outstanding134
Operating Cycle201.07
Days of Payables Outstanding60
Cash Conversion Cycle141
Receivables Turnover5.41
Payables Turnover6.07
Inventory Turnover2.73
Fixed Asset Turnover1.94
Asset Turnover0.33

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.54, and free cash flow per share, -0.58, depict cash generation on a per-share basis. The cash per share value, 1.44, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.41, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.54
Free Cash Flow per Share-0.58
Cash per Share1.44
Operating Cash Flow Sales Ratio-0.41
Free Cash Flow to Operating Cash Flow Ratio1.07
Cash Flow Coverage Ratio-0.64
Short Term Coverage Ratio-0.68
Capital Expenditure Coverage Ratio-15.29
Dividend Paid and Capex Coverage Ratio-15.29

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 21.00%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.42, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.38%, and total debt to capitalization, 29.36%, ratios shed light on its capital structure. An interest coverage of -15.35 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio21.00%
Debt Equity Ratio0.42
Long Term Debt to Capitalization2.38%
Total Debt to Capitalization29.36%
Interest Coverage-15.35
Cash Flow to Debt Ratio-0.64
Company Equity Multiplier1.98

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.34, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.94, reflects the portion of profit attributed to each share. The book value per share, 2.06, represents the net asset value distributed per share, while the tangible book value per share, 0.70, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.34
Net Income Per Share-0.94
Book Value Per Share2.06
Tangible Book Value Per Share0.70
Shareholders Equity Per Share2.06
Interest Debt Per Share0.91
Capex Per Share-0.04

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 8.57%, indicates top-line expansion, while the gross profit growth, 36.16%, reveals profitability trends. EBIT growth, 45.75%, and operating income growth, 45.75%, offer insights into operational profitability progression. The net income growth, 60.73%, showcases bottom-line expansion, and the EPS growth, 61.32%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth8.57%
Gross Profit Growth36.16%
EBIT Growth45.75%
Operating Income Growth45.75%
Net Income Growth60.73%
EPS Growth61.32%
EPS Diluted Growth61.32%
Weighted Average Shares Growth1.09%
Weighted Average Shares Diluted Growth1.09%
Operating Cash Flow Growth51.56%
Free Cash Flow Growth50.51%
10-Year Revenue Growth per Share-51.92%
5-Year Revenue Growth per Share-52.85%
3-Year Revenue Growth per Share-29.94%
10-Year Operating CF Growth per Share-775.72%
5-Year Operating CF Growth per Share13.96%
3-Year Operating CF Growth per Share-155.53%
10-Year Net Income Growth per Share-51.87%
5-Year Net Income Growth per Share36.63%
3-Year Net Income Growth per Share-28.15%
10-Year Shareholders Equity Growth per Share-45.91%
5-Year Shareholders Equity Growth per Share13.36%
3-Year Shareholders Equity Growth per Share6.82%
Receivables Growth13.77%
Inventory Growth-4.38%
Asset Growth-17.23%
Book Value per Share Growth298.17%
Debt Growth-4.33%
R&D Expense Growth-32.60%
SGA Expenses Growth-23.72%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 221,449,600, captures the company's total value, considering both debt and equity. Income quality, 0.58, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 33.34%, indicates the value of non-physical assets, and capex to operating cash flow, 6.54%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value221,449,600
Income Quality0.58
Research and Development to Revenue24.40%
Intangibles to Total Assets33.34%
Capex to Operating Cash Flow6.54%
Capex to Revenue-2.66%
Capex to Depreciation-18.65%
Stock-Based Compensation to Revenue12.34%
Graham Number6.61
Return on Tangible Assets-34.67%
Graham Net Net-0.25
Working Capital48,888,000
Tangible Asset Value55,478,000
Net Current Asset Value-1,650,000
Average Receivables18,470,000
Average Payables8,575,000
Average Inventory21,003,000
Days Sales Outstanding67
Days Payables Outstanding60
Days of Inventory On Hand134
ROIC-27.45%
ROE-0.46%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.18, and the price to book ratio, 1.18, reflect the market's valuation relative to the company's book value. The price to sales ratio, 8.68, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -20.02, and price to operating cash flows, -4.44, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.18
Price to Book Ratio1.18
Price to Sales Ratio8.68
Price Cash Flow Ratio-4.44
Price Earnings to Growth Ratio-0.07
Enterprise Value Multiple-18.05
Price Fair Value1.18
Price to Operating Cash Flow Ratio-4.44
Price to Free Cash Flows Ratio-20.02
Price to Tangible Book Ratio1.07
Enterprise Value to Sales2.08
Enterprise Value Over EBITDA-4.63
EV to Operating Cash Flow-5.12
Earnings Yield-42.67%
Free Cash Flow Yield-26.36%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Standard BioTools Inc. (LAB) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -2.574 in 2024.

What is the ticker symbol of Standard BioTools Inc. stock?

The ticker symbol of Standard BioTools Inc. stock is LAB.

What is company IPO date?

IPO date of Standard BioTools Inc. is 2011-02-10.

What is company current share price?

Current share price is 2.410 USD.

What is stock market cap today?

The market cap of stock today is 923148090.000.

What is PEG ratio in 2024?

The current -0.074 is -0.074 in 2024.

What is the number of employees in 2024?

In 2024 the company has 534.